Julie Bertrand

Generating author description...

All published works

Action	Title	Year	Authors
+	Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?	2024	Morgane Philipp Adrien Tessier Mark Donnelly Lanyan Fang Kairui Feng Liang Zhao Stella Grosser Guoying Sun Wanjie Sun France Mentré
+	Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models—a New Method Based on Metropolis-Hastings Algorithm	2024	Mélanie Guhl Julie Bertrand Lucie Fayette François Mercier Emmanuelle Comets
+ PDF Chat	Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies	2023	Coralie Tardivon Florence Loingeville Mark Donnelly Kairui Feng Wanjie Sun Guoying Sun Stella Grosser Liang Zhao Lanyan Fang France Mentré
+ PDF Chat	Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates	2022	Aurélien Marc Romain Marlin Flora Donati Mélanie Prague Marion Kerioui Cécile Herate Marie Alexandre Nathalie Dereuddre‐Bosquet Julie Bertrand Vanessa Contreras
+ PDF Chat	Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	2022	Mélanie Guhl François Mercier Carsten Hofmann Satish Sharan Mark Donnelly Kairui Feng Wanjie Sun Guoying Sun Stella Grosser Liang Zhao
+ PDF Chat	Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer	2022	Marion Kerioui M. Beaulieu Solène Desmée Julie Bertrand François Mercier Jin Y. Jin René Bruno Jérémie Guedj
+ PDF Chat	Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models	2022	Marion Kerioui Julie Bertrand René Bruno François Mercier Jérémie Guedj Solène Desmée
+	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness	2021	Aurélien Marc Marion Kerioui François Blanquart Julie Bertrand Natàlia Casamitjana Marc Corbacho-Monné Michael Marks Jérémie Guedj
+	Author response: Quantifying the relationship between SARS-CoV-2 viral load and infectiousness	2021	Aurélien Marc Marion Kerioui François Blanquart Julie Bertrand Natàlia Casamitjana Marc Corbacho-Monné Michael Marks Jérémie Guedj
+	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness	2021	Aurélien Marc Marion Kerioui François Blanquart Julie Bertrand Natàlia Casamitjana Marc Corbacho-Monné Michael Marks Jérémie Guedj
+ PDF Chat	Impact of study design and statistical model in pharmacogenetic studies with gene‐treatment interaction	2021	Camille Couffignal France Mentré Julie Bertrand
+ PDF Chat	New Model–Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling	2020	Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Kairui Feng Wanjie Sun Jing Han Stella Grosser Liang Zhao Lanyan Fang
+	Bayesian inference using Hamiltonian Monte‐Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy	2020	Marion Kerioui François Mercier Julie Bertrand Coralie Tardivon René Bruno Jérémie Guedj Solène Desmée
+	Efficient model-based bioequivalence testing	2020	Kathrin Möllenhoff Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Liang Zhao Lanyan Fang Guoying Sun Stella Grosser France Mentré
+	Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load	2020	António Gonçalves Julie Bertrand Ruian Ke Emmanuelle Comets Xavier de Lamballerie Denis Malvy Andrés Pizzorno Olivier Terrier Manuel Rosa Calatrava France Mentré
+	Efficient model-based Bioequivalence Testing	2020	Kathrin Möllenhoff Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Guoying Sun Stella Grosser Liang Zhao Lanyan Fang Holger Dette
+	Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM	2020	François Riglet France Mentré Christine Veyrat‐Follet Julie Bertrand
+	Efficient model-based Bioequivalence Testing	2020	Kathrin Möllenhoff Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Guoying Sun Stella Grosser Liang Zhao Lanyan Fang France Mentré
+ PDF Chat	Bioequivalence and Statistics in Clinical Pharmacology	2017	Julie Bertrand
+ PDF Chat	Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests	2016	Anne Prigent‐Tessier Julie Bertrand Marylore Chenel Emmanuelle Comets
+	<b><i>Mixed Effects Models for the Population Approach. Models, Tasks, Methods and Tools</i></b>, by Marc Lavielle	2015	Julie Bertrand
+	Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics	2015	Julie Bertrand Maria De Iorio David J. Balding
+ PDF Chat	Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates	2015	Adrien Tessier Julie Bertrand Marylore Chenel Emmanuelle Comets
+	Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models	2013	Julie Bertrand David J. Balding
+	Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose–Response Models	2012	Elodie L. Plan Alan Maloney France Mentré Mats O. Karlsson Julie Bertrand
+ PDF Chat	Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models	2011	Julie Bertrand Emmanuelle Comets Marylore Chenel France Mentré
+	Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model	2011	Julie Bertrand Céline M. Laffont France Mentré Marylore Chenel Emmanuelle Comets
+ PDF Chat	Pharmacogenetics in population Pharmacokinetics: tests and model selection	2009	Julie Bertrand
+	Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm	2009	Julie Bertrand Emmanuelle Comets Céline M. Laffont Marylore Chenel France Mentré
+	Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters	2008	Julie Bertrand Emmanuelle Comets France Mentré
+	Nonlinear Mixed Effects Estimation Algorithms: A Performance Comparison for Continuous Pharmacodynamic Population Models	2007	Elodie L. Plan Alan Maloney Mats O. Karlsson Julie Bertrand

Common Coauthors

Coauthor	Papers Together
France Mentré	14
Emmanuelle Comets	9
Jérémie Guedj	8
Marion Kerioui	7
Lanyan Fang	7
Stella Grosser	7
Liang Zhao	5
Satish Sharan	5
François Mercier	5
Marylore Chenel	5
Florence Loingeville	5
Thu Thuy Nguyen	4
Wanjie Sun	4
Kairui Feng	4
Aurélien Marc	4
Kathrin Möllenhoff	4
Holger Dette	4
Natàlia Casamitjana	3
François Blanquart	3
Michael Marks	3
Marc Corbacho-Monné	3
Mark Donnelly	3
René Bruno	3
Guoying Sun	3
Alan Maloney	2
Coralie Tardivon	2
Céline M. Laffont	2
Liang Zhao	2
Solène Desmée	2
Mélanie Guhl	2
Guoying Sun	2
David J. Balding	2
Mats O. Karlsson	2
Adrien Tessier	2
Elodie L. Plan	2
Carsten Hofmann	1
Morgane Philipp	1
Lucie Fayette	1
M. Beaulieu	1
Jin Y. Jin	1
Sylvie van der Werf	1
Marie Alexandre	1
Patrick F. Smith	1
Cécile Hérate	1
Xavier de Lamballerie	1
Olivier Terrier	1
Solène Desmée	1
Pauline Maisonnasse	1
Jing Han	1
Camille Couffignal	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Convergence of a stochastic approximation version of the EM algorithm	1999	Bernard Delyon Marc Lavielle Éric Moulines	10
+	Evaluation by simulation of tests based on non‐linear mixed‐effects models in pharmacokinetic interaction and bioequivalence cross‐over trials	2005	Xavière Panhard France Mentré	8
+ PDF Chat	Model‐based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm	2011	Anne Dubois Marc Lavielle Sandro Gsteiger Etienne Pigeolet France Mentré	7
+	Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm	2009	Julie Bertrand Emmanuelle Comets Céline M. Laffont Marylore Chenel France Mentré	6
+	Maximum likelihood estimation in nonlinear mixed effects models	2004	Estelle Kuhn Marc Lavielle	6
+ PDF Chat	A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability	1987	Donald J. Schuirmann	6
+ PDF Chat	Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models	2011	Julie Bertrand Emmanuelle Comets Marylore Chenel France Mentré	6
+	Bioequivalence Tests Based on Individual Estimates Using Non-compartmental or Model-Based Analyses: Evaluation of Estimates of Sample Means and Type I Error for Different Designs	2009	Anne Dubois Sandro Gsteiger Etienne Pigeolet France Mentré	5
+ PDF Chat	Parameter Estimation in Nonlinear Mixed Effect Models Using <b>saemix</b>, an <i>R</i> Implementation of the SAEM Algorithm	2017	Emmanuelle Comets Audrey Lavenu Marc Lavielle	5
+ PDF Chat	Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0	2009	Caroline Bazzoli Sylvie Retout France Mentré	4
+	Efficient model-based bioequivalence testing	2020	Kathrin Möllenhoff Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Liang Zhao Lanyan Fang Guoying Sun Stella Grosser France Mentré	4
+	Nonlinear Mixed Effects Models for Repeated Measures Data	1990	Mary J. Lindstrom Douglas M. Bates	4
+	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort	2021	Nadège Néant Guillaume Lingas Quentin Le Hingrat Jade Ghosn Ilka Engelmann Quentin Lepiller Alexandre Gaymard Virginie Ferré Cédric Hartard Jean‐Christophe Plantier	4
+	Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models	2013	Julie Bertrand David J. Balding	4
+	Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling	2010	Thorsten Lehr H Schaefer Alexander Staab	4
+	Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters	2008	Julie Bertrand Emmanuelle Comets France Mentré	4
+	Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions	2009	Radojka M. Savić Mats O. Karlsson	4
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	3
+ PDF Chat	Estimating the Dimension of a Model	1978	Gideon Schwarz	3
+ PDF Chat	Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches	2015	Solène Desmée France Mentré Christine Veyrat‐Follet Jérémie Guedj	3
+ PDF Chat	Impact of modelling intra‐subject variability on tests based on non‐linear mixed‐effects models in cross‐over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients	2006	Xavière Panhard Anne‐Marie Taburet Christophe Piketti France Mentré	3
+	An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses	2014	Chen‐An Tsai Chih‐Yang Huang Jen‐pei Liu	3
+	SARS-CoV-2 viral dynamics in non-human primates	2021	António Gonçalves Pauline Maisonnasse Flora Donati Mélanie Albert Sylvie Behillil Vanessa Contreras Thibaut Naninck Romain Marlin Caroline Solas Andrés Pizzorno	3
+ PDF Chat	Seemingly unrelated nonlinear regressions	1975	A. Ronald Gallant	3
+ PDF Chat	The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects model	2007	Adeline Samson Marc Lavielle France Mentré	3
+	Statistical Issues in a Modeling Approach to Assessing Bioequivalence or PK Similarity with Presence of Sparsely Sampled Subjects	2004	Chuanpu Hu Katy H. P. Moore Yong H. Kim Mark Sale	3
+	Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling	2011	Anne Dubois Sandro Gsteiger Sigrid Balser Etienne Pigeolet Jean‐Louis Steimer Goonaseelan Pillai France Mentré	3
+ PDF Chat	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies	2018	Vincent Madelain Sylvain Baize Frédéric Jacquot Stéphanie Reynard Alexandra Fizet Stéphane Barron Caroline Solas Bruno Lacarelle Caroline Carbonnelle France Mentré	3
+	Aerosol transmission of SARS-CoV-2? Evidence, prevention and control	2020	Song Tang Yixin Mao Rachael M. Jones Qiyue Tan John S. Ji Na Li Jin Shen Yuebin Lv Lijun Pan Pei Ding	3
+ PDF Chat	Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis	2016	Maria Sudell Ruwanthi Kolamunnage‐Dona Catrin Tudur Smith	3
+	Using the SAEM Algorithm for Mechanistic Joint Models Characterizing the Relationship Between Nonlinear PSA Kinetics and Survival in Prostate Cancer Patients	2016	Solène Desmée France Mentré Christine Veyrat‐Follet Bernard Sébastien Jérémie Guedj	3
+	Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer	2017	Solène Desmée France Mentré Christine Veyrat‐Follet Bernard Sébastien Jérémie Guedj	3
+ PDF Chat	New Model–Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling	2020	Florence Loingeville Julie Bertrand Thu Thuy Nguyen Satish Sharan Kairui Feng Wanjie Sun Jing Han Stella Grosser Liang Zhao Lanyan Fang	3
+	Joint Models for Longitudinal and Time-to-Event Data	2012	Dimitris Rizopoulos	3
+ PDF Chat	Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models	2018	Simon Buatois Sebastian Ueckert Nicolas Frey Sylvie Retout France Mentré	3
+	Population modelling in drug development	1999	Lewis B. Sheiner Jon Wakefield	2
+	Pharmacokinetic/Pharmacodynamic Modeling in Drug Development	2000	Lewis B. Sheiner Jean‐Louis Steimer	2
+	Bioequivalence; Its History, Practice, and Future	2009	Kamal K. Midha Gordon McKay	2
+	None	1997	Marc Lavielle Éric Moulines	2
+	Multiparameter Hypothesis Testing and Acceptance Sampling	1980	Roger L. Berger	2
+	Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science	2005	Goonaseelan Pillai France Mentré Jean‐Louis Steimer	2
+	Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach.	1996	Helen S. Pentikis James D. Henderson Nhan L. Tran Thomas M. Ludden	2
+ PDF Chat	Implementation and Evaluation of the SAEM Algorithm for Longitudinal Ordered Categorical Data with an Illustration in Pharmacokinetics–Pharmacodynamics	2010	Radojka M. Savić France Mentré Marc Lavielle	2
+	Power of the two one-sided tests procedure in bioequivalence	1990	Kem F. Phillips	2
+	The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure	2002	N. J. Law	2
+ PDF Chat	Coupling a stochastic approximation version of EM with an MCMC procedure	2004	Estelle Kuhn Marc Lavielle	2
+ PDF Chat	The Effective Sample Size and an Alternative Small-Sample Degrees-of-Freedom Method	2009	Christel Faes Geert Molenberghs Marc Aerts Geert Verbeke Michael G. Kenward	2
+	Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose–Response Models	2012	Elodie L. Plan Alan Maloney France Mentré Mats O. Karlsson Julie Bertrand	2
+	Probabilities and sample sizes for the two one-sided tests procedure	1993	David R. Bristol	2
+	COMPARISON OF POPULATION PHARMACOKINETIC MODELING METHODS USING SIMULATED DATA: RESULTS FROM THE POPULATION MODELING WORKGROUP	1997	Denise J. Roe Edward F. Vonesh Russell D. Wolfinger Florence Mesnil Alain Mallet	2